The Cultivation Modality and Barrier Maturity Modulate the Toxicity of Industrial Zinc Oxide and Titanium Dioxide Nanoparticles on Nasal, Buccal, Bronchial, and Alveolar Mucosa Cell-Derived Barrier Models

• Published in: International journal of molecular sciences Vol. 24; no. 6; p. 5634
• Main Authors: Stuetz, Helene, Reihs, Eva I, Neuhaus, Winfried, Pflüger, Maren, Hundsberger, Harald, Ertl, Peter, Resch, Christian, Bauer, Gerald, Povoden, Günter, Rothbauer, Mario
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15-03-2023; MDPI
• Subjects: Aerosols; Alveoli; Analysis; Animals; Apoptosis; barrier health; barrier integrity; Cell culture; Cell lines; Cell size; Cell viability; Corticosteroids; Cultivation; Cytotoxicity; Drug delivery systems; Electrical resistivity; Exposure; human mucosa models; Humans; Hydrocortisone; Inhalation; Interfaces; Investigations; Liquid-liquid interfaces; Localization; Maturity; Mucosa; Mucous Membrane; Nanomaterials; Nanoparticles; Nanoparticles - toxicity; Nanotechnology; nanotoxicology; Physiology; Reproducibility; Respiration; Respiratory system; Standardization; Titanium; Titanium - toxicity; Titanium dioxide; Toxicity; Toxins; Zinc oxide; Zinc Oxide - toxicity; Zinc oxides; Austria; titanium dioxide; barrier integrity; barrier health; human mucosa models; zinc oxide; nanotoxicology
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24065634

As common industrial by-products, airborne engineered nanomaterials are considered important environmental toxins to monitor due to their potential health risks to humans and animals. The main uptake routes of airborne nanoparticles are nasal and/or oral inhalation, which are known to enable the transfer of nanomaterials into the bloodstream resulting in the rapid distribution throughout the human body. Consequently, mucosal barriers present in the nose, buccal, and lung have been identified and intensively studied as the key tissue barrier to nanoparticle translocation. Despite decades of research, surprisingly little is known about the differences among various mucosa tissue types to tolerate nanoparticle exposures. One limitation in comparing nanotoxicological data sets can be linked to a lack of harmonization and standardization of cell-based assays, where (a) different cultivation conditions such as an air-liquid interface or submerged cultures, (b) varying barrier maturity, and (c) diverse media substitutes have been used. The current comparative nanotoxicological study, therefore, aims at analyzing the toxic effects of nanomaterials on four human mucosa barrier models including nasal (RPMI2650), buccal (TR146), alveolar (A549), and bronchial (Calu-3) mucosal cell lines to better understand the modulating effects of tissue maturity, cultivation conditions, and tissue type using standard transwell cultivations at liquid-liquid and air-liquid interfaces. Overall, cell size, confluency, tight junction localization, and cell viability as well as barrier formation using 50% and 100% confluency was monitored using trans-epithelial-electrical resistance (TEER) measurements and resazurin-based Presto Blue assays of immature (e.g., 5 days) and mature (e.g., 22 days) cultures in the presence and absence of corticosteroids such as hydrocortisone. Results of our study show that cellular viability in response to increasing nanoparticle exposure scenarios is highly compound and cell-type specific (TR146 6 ± 0.7% at 2 mM ZnO (ZnO) vs. ~90% at 2 mM TiO
(TiO
) for 24 h; Calu3 93.9 ± 4.21% at 2 mM ZnO vs. ~100% at 2 mM TiO
). Nanoparticle-induced cytotoxic effects under air-liquid cultivation conditions declined in RPMI2650, A549, TR146, and Calu-3 cells (~0.7 to ~0.2-fold), with increasing 50 to 100% barrier maturity under the influence of ZnO (2 mM). Cell viability in early and late mucosa barriers where hardly influenced by TiO
as well as most cell types did not fall below 77% viability when added to Individual ALI cultures. Fully maturated bronchial mucosal cell barrier models cultivated under ALI conditions showed less tolerance to acute ZnO nanoparticle exposures (~50% remaining viability at 2 mM ZnO for 24 h) than the similarly treated but more robust nasal (~74%), buccal (~73%), and alveolar (~82%) cell-based models.